Research ArticleClinical Investigations
PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of 89Zr-Cetuximab
Nikolaos E. Makris, Ronald Boellaard, Arthur van Lingen, Adriaan A. Lammertsma, Guus A.M.S. van Dongen, Henk M. Verheul, Catharina W. Menke and Marc C. Huisman
Journal of Nuclear Medicine February 2015, 56 (2) 249-254; DOI: https://doi.org/10.2967/jnumed.114.147819
Nikolaos E. Makris
1Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; and
Ronald Boellaard
1Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; and
Arthur van Lingen
1Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; and
Adriaan A. Lammertsma
1Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; and
Guus A.M.S. van Dongen
1Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; and
Henk M. Verheul
2Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
Catharina W. Menke
2Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
Marc C. Huisman
1Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands; and
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 56, Issue 2
February 1, 2015
PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of 89Zr-Cetuximab
Nikolaos E. Makris, Ronald Boellaard, Arthur van Lingen, Adriaan A. Lammertsma, Guus A.M.S. van Dongen, Henk M. Verheul, Catharina W. Menke, Marc C. Huisman
Journal of Nuclear Medicine Feb 2015, 56 (2) 249-254; DOI: 10.2967/jnumed.114.147819
PET/CT-Derived Whole-Body and Bone Marrow Dosimetry of 89Zr-Cetuximab
Nikolaos E. Makris, Ronald Boellaard, Arthur van Lingen, Adriaan A. Lammertsma, Guus A.M.S. van Dongen, Henk M. Verheul, Catharina W. Menke, Marc C. Huisman
Journal of Nuclear Medicine Feb 2015, 56 (2) 249-254; DOI: 10.2967/jnumed.114.147819
Jump to section
Related Articles
Cited By...
- Click-to-Release: Cleavable Radioimmunoimaging with 89Zr-DFO-Trans-Cyclooctene-Trastuzumab Increases Tumor-to-Blood Ratio
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT-Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer
- ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment
- PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging